Investor FAQs


Ocera became a public company effective July 15, 2013 resulting from a reverse merger with Tranzyme, Inc. Tranzyme became a publicly traded company on April 1, 2011 through an initial public offering (IPO).

Ocera shares trade on the NASDAQ Global Market under the symbol "OCRX".

At the time of the merger with Tranzyme, Inc., Tranzyme was a public company traded on the NASDAQ Global Market under the symbol “TZYM”. Since, prior to the merger, Ocera was privately held, NASDAQ carries forward the 52-week history of the former public entity, in this case Tranzyme.

Ocera maintains operations in both California and North Carolina in the U.S. The company's headquarters are located in Palo Alto, California.  Business development, clinical development and regulatory activities are conducted in Durham, North Carolina.

Ocera does not offer a direct stock purchase program.

The company's fiscal year ends on December 31.

Ocera's SEC filings are listed under the Financial Information tab in the Investor Relations section of the Ocera website.

No. Ocera does not anticipate paying any dividends on its capital stock in the foreseeable future.

Ocera's transfer agent can be contacted in writing, by phone or via email at:

Continental Stock Transfer & Trust Company
17 Battery Place
New York, NY 10004

Click here to contact investor relations.

Please submit your question using the form below.

* Indicates required field